AU Patent

AU2014214846A1 — ERK inhibitors and uses thereof

Assigned to Celgene Avilomics Research Inc · Expires 2015-07-23 · 11y expired

What this patent protects

Compounds, compositions thereof, and methods for inhibiting one or both ERK1 and ERK2 kinases are provided.

USPTO Abstract

Compounds, compositions thereof, and methods for inhibiting one or both ERK1 and ERK2 kinases are provided.

Drugs covered by this patent

Patent Metadata

Patent number
AU2014214846A1
Jurisdiction
AU
Classification
—
Expires
2015-07-23
Drug substance claim
No
Drug product claim
No
Assignee
Celgene Avilomics Research Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.